DTx Europe
Partners 2019
DTx Europe Partners
DTx in 60 Seconds
Key Numbers of DTx
100+
Attendees
Be part of the 100+ person audience of senior executives from digital therapeutic companies, pharma, investors and healthcare professionals
40+
Expert Speakers
Learn from the industry-defining speaker faculty, comprised of the pioneers of the industry and the most exciting new-comers form Europe, USA and beyond
16+
Hours of Learning
Hear how digital therapeutics are being developed and commercialised in Europe and globally through case-studies, panels, workshops and roundtables
What people are saying about the DTx Series
“I found this conference eye-opening and had many interesting conversations. I am blown away by the Digital Therapeutics community and its commitment to value-based care”
Founder and Executive Director, Cures Within Reach for Cancer
Laura Kleiman
“DTx is the must attend event in our industry”
CEO, Akili Interactive
Eddie Martucci
“The DTx Series is a fantastic set of meetings. The quality of the investors, entrepreneurs and companies never fails to impress me, and I always leave having learned a lot”
General Partner, JAZZ Venture Partners
John Spinale
“The conference was tangible, specific and open. I have never been to a conference of this size with such richness of discussion”
Health Data Policy Director, Novartis
Frederico Calado
“Thanks for catalyzing the industry forward in this emerging field. Looking forward to the next one”
Global Director, Innovation, Johnson and Johnson Technology
Cris de Luca
“DTx is an inclusive event, where the participants truly believe that the rising tide will raise all boats”
Founder and CEO, MyMee Inc
Mette Dyhrberg
Expert Speaker Faculty
Konstantin is a serial entrepreneur. His last company foodora, a global food delivery company was sold to delivery hero in 2015. He now builds a digital therapeutics company called Kaia Health. He holds a dual Masters in Finance and Energy Systems from Columbia University and a Bachelor’s degree from Technical University.
Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University
Jessica is a Strategic Adviser to the Digital Therapeutics Alliance, whose mission is to broaden the understanding, adoption, and integration of clinically-validated digital therapeutics into healthcare through education, advocacy, and research. She is also Digital Health Manager on clinical trials and personalized medicine projects for respiratory disease at Bellvitge Hospital in Barcelona. She worked for more than 13 years with the WHO on numerous digital health projects for health system strengthening and digital health best practices. Consultancies include World Bank digital for global health (2010), mHealth app evaluation guidelines for Europe (2015), and EU regulatory process for US digital diagnostic start-ups (2016). She has an MSc from the Medical College of Georgia, an MA from the University of Trento, and is currently enrolled in the PhD program in BioMedicine at the University of Barcelona.
Dr. Maricich leads the Clinical/Regulatory team at Pear Therapeutics as the Chief Medical Officer and Head of Clinical Development. He collaborates with the executive team on management and strategy. He leads and manages the clinical development programs from Discovery/TPP to Therapeutic, Translational, Clinical Development, through Regulatory submission and prosecution. He leads the team for Pear’s reSET clinical program, including the team and strategy for their De Novo Request/Submission of reSET to the FDA, which was cleared by the FDA as the first prescription digital therapeutic to treat disease. In addition to overseeing subsequent pipeline programs, including reSET-O (1st drug/software combination), Dr. Maricich leads Medical Affairs, responsible for successful coverage decisions and works closely with the Pear BD team on business development and biopharma deals and partnerships.
André is an experienced startup executive, business and sales manager, leader, and strategist. He is an expert in inside and field sales management, pharmaceutical and medical products marketing and sales, commercial strategy planning, and healthcare topics. He has extensive knowledge in B2B and B2C business, software and hardware product portfolios and offerings in the US and Germany. His passion for the impact technology can have on a large scale has been the red thread throughout his career. André holds doctorates from the University of Würzburg in medicine and the University of Freiburg in dental medicine.
André joined Sandoz in June 2018 from his role as CSO at Thermondo GmbH, an integrated energy company offering state-of-the-art energy efficiency services and applying digital process excellence and quality management. This year, The Financial Times named Thermondo #2 fastest growing company in Europe as well as one of the 100 most influential clean-tech companies in the world.
Before that, André was Vice President of Local Sales at Zocdoc, Inc. Zocdoc is an online service that identifies in-network neighborhood physicians, books appointments, shares patient reviews, provides appointment and check-up reminders, and automatically fills in paperwork. Zocdoc is free for patients and available across the United States.
Edward Cox was appointed as the new Chairman of the Board and the Chief Executive Officer of Dthera in connection with the closing of the EveryStory Transaction. Mr. Cox also continues to serve as EveryStory’s President and Chief Executive Officer and Chairman and a member of EveryStory’s Board of Directors, positions he has held since February 6, 2015. Prior to that, he served as a Vice President and Executive Officer of Apricus Biosciences, Inc., a publicly traded company, since December 2009, in roles leading Commercial Development, Business Development, Investor Relations, and Corporate Development. Mr. Cox holds a Master of Science in Management degree from the Warrington College of Business Administration at the University of Florida.
Kim Baden-Kristensen is the CEO and Co-founder of Brain+, an award winning Danish health tech company specializing in digital therapeutics for neurorehabilitation of disorders and injuries to the Central Nervous System (CNS).
Kim is intensively engaged in digital health care policy debates and initiatives on the European level. He is a founding member of the Digital Therapeutics Partnership, a global non-for-profit with a mission to enhance patient outcomes and quality of care with clinically-validated digital therapeutics.
Kim is intensively engaged in digital health care policy debates and initiatives on the European level. He is a founding member of the Digital Therapeutics Partnership, a global non-for-profit with a mission to enhance patient outcomes and quality of care with clinically-validated digital therapeutics.
Kim is an expert within digital therapeutics, with particularly emphasis on neurogame-based rehabilitation and gamified behavioral therapy.
Kim holds an MSc. In Innovation Management from Copenhagen Business School, a Health Care Innovation Management degree from Harvard Business School, and a minor in Cognitive Neuroscience from Copenhagen University.
Edward is Investment Director in the New Businesses fund with M Ventures, the Corporate Venture Capital arm of Merck KGaA, Darmstadt, Germany. The New Businesses fund invests globally in transformational ideas driven by great entrepreneurs. The fund seeks to invest in strategic opportunities beyond Merck’s current businesses, make cross over investments between businesses and invest in digitization opportunities. M Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. The total volume of the venture fund is €300 million.
Matthias is a physician by training and holds a medical doctorate degree from the University of Ulm, Germany. He has gained both inpatient and outpatient medical expertise in various healthcare systems around the world. Matthias joined GAIA 17 years ago and takes the responsibility for the national and international business development and licensing activities with payer and physician organisations as well as industry partners. And when not travelling the world for business, he travels the world for leisure.
Dr Indra Joshi is the Clinical Lead for NHS England’s Empower the Person Portfolio overseeing the national citizen facing digital initiatives within the NHS with a focus on Real World Evidence, data, digital health innovation standards and AI.
Indra has a unique portfolio with experience stretching across policy, governance, digital health and marketing, national project strategy and implementation; whilst remaining true to her professional training as an emergency medic.
She is the Clinical Director of One HealthTech – a network which champions and supports underrepresented groups in health innovation, particularly women, to be the future leaders in healthcare. Alongside she is a Vice Chair for the British Computer Society (Health), an international speaker and consultant on digital health, an expedition medic, and most importantly a mum to two wonderful little munchkins.
Sahil Kirpekar is the Head of Business Development Europe at Otsuka Pharmaceutical and is responsible for bringing in Pharmaceutical and Digital health opportunities into Otsuka’s Global business portfolio. He sits on Otsuka’s Global Business Development Strategy Committee, and has over the last 2 years delivered ~€1Bn worth of deals.
Sahil has been in various commercial roles at Otsuka prior to this position, and across the life sciences industry before that. In the past, he has helped set up the Asia-Pacific practice at Double Helix Consulting (acquired by McCann Health) with offices in Singapore and China. Sahil has also held roles within the World Health Organisation and Medimmune prior to that. He co-founded Inderm, a startup to develop intradermal drug delivery devices to overcome adherence challenges in Tuberculosis.
He is a Medical Doctor, and also holds a Masters in Bioscience Enterprise from the University of Cambridge.
Samantha Roberts has recently been appointed as Chief Executive of the Accelerated Access Collaborative, the national umbrella organisation for health innovation, hosted in NHS England and NHS Improvement.
She originally trained as a doctor and practiced medicine in South Africa, the UK, and Australia before undertaking an MBA and joining McKinsey and Company, where she worked in a wide range of industries before specialising in healthcare.
After McKinsey she moved into the NHS as a senior manager at a large teaching hospital in London (UCLH) and a director in an Academic Health Sciences Centre and Network (UCLPartners). Before taking on the role of Director of Innovation, Research and Life Sciences at NHS England and NHS Improvement last year.
Over the last five years she has become involved in research, working with health economic models to inform evidence-based policy, initially at the London School of Economics before moving to the University of Oxford to undertake a DPhil (PhD).
Florian started his career working in Silicon Valley for an Equity Research firm focused on technology and renewable energy companies. He continued working for Google advising clients from the energy and retail industry. Before joining Sandoz he worked four years for a Berlin-based start-up in sales operations and product management. At Sandoz his primary focus are Digital Therapeutics.
Elena Mustatea is Co-founder and CEO of Bold Health, a startup developing digital therapeutics for functional and autoimmune conditions, leveraging behavioural medicine and machine learning to deliver personalised and highly effective treatments and self management support. Elena was named Forbes’ Europe 30 Under 30 Finance List in 2018 in her role as venture capital investor with leading European VC fund Atomico, and previously also worked in investment banking at J.P. Morgan and Goldman Sachs, management consulting at Oliver Wyman, and ran a media business.
Atse Aukes is Head of Product at Tired of Cancer. With a background in Business Administration, Atse has almost ten years of broad IT experience in the field of eHealth, particularly in mental healthcare.
Atse was previously product manager of one of the largest eHealth platforms in the Netherlands in the field of mental health. During that time, he developed insight into online (evidence-based) interventions, patient reported outcomes, and integration challenges in a blended care setting. That’s how he was at the foundation of Koppeltaal, the Dutch national integration and information standard for the mental health care providers and was one of the first to use it.
Within Tired of Cancer, Atse is responsible for supervising the development & maintenance of Untire, research projects and IT legal & compliance matters. He gets excited by state-of-the-art techniques such as A.I and is keen to look at the data himself to gain new insights. His passion really lies in being meaningful to the end users; there is such a large group of people who benefit from the app. Therefore, his day starts off good when a new positive review has arrived.
With great enthusiasm, Atse is using all his skills to make Untire a success and by that help many cancer patients worldwide.
Brian Clancy is Co-Lead for AppScript, the world’s leading curation, prescribing, and studies platform for digital patient engagement tools. Prior to AppScript, Brian had a seven-year career as a strategy consultant to leading and emerging health technology and pharmaceutical companies. He is an author of various academic and industry publications on personalized medicine and digital health, including the recently published report by the IQVIA Institute for Human Data Science entitled ``The Growing Value of Digital Health.`` His research has been featured in The Economist, The Lancet, Tech Crunch, and Eric Topol's Twitter feed. He is an inventor in the field of app curation and a conference speaker on the topic of technical innovation in healthcare. Brian holds Bachelor of Science and Bachelor of Arts degrees in Molecular Genetics and Economics from the University of Rochester.
Before joining Voluntis, Alexandre worked for over 15 years in the pharmaceutical industry. At Sanofi, he notably headed the Group's strategic planning and M&A for France, where he strongly contributed to building the Diabeo partnership with Sanofi, CERITD and Voluntis. Alexandre is a graduate of HEC Paris and Sciences Po Paris. He holds a master's degree in health economics from Paris-Dauphine University.
Before joining Voluntis, Alexandre worked for over 15 years in the pharmaceutical industry. At Sanofi, he notably headed the Group's strategic planning and M&A for France, where he strongly contributed to building the Diabeo partnership with Sanofi, CERITD and Voluntis. Alexandre is a graduate of HEC Paris and Sciences Po Paris. He holds a master's degree in health economics from Paris-Dauphine University.
Jim O’Donoghue, President of S3 Connected Health, has 16 years’ experience in designing and delivering innovative connected health services and solutions. Having led the development and deployment of technology-enabled patient services for rare and chronic conditions that have been rolled out across 40 countries, Jim is focused on the future of digital patient services and the integration of solutions into clinical care pathways as we move towards Value-Based Care. An advocate of empowering patient self-management, Jim has overseen the design of the largest telehealth program in the UK and the largest chronic disease management program in Europe.
Strategy delivery lead for NHS England, in this role I apply my digital and transformation experience to help support the delivery of integrated patient-centred care; with a digital thread, working with local and regional teams on the NHS App, Apps library, Personal Health Records and more. My background includes COO of international patient communications start-up, empowering children with chronic conditions; digital health start-up consultant, and a more recent Masters in International Health Policy with a focus on digital health.
Matthias is passionate about tech enabled innovation in health care and beyond which perfectly fits his current role at Allianz Partners, where he leads all health related innovation efforts. Before joining Allianz, he was working for the Boston Consulting Group as a strategy consultant and also leading the Digital Business Unit at Carl Zeiss Vision. Dr. Matthias Kuss holds a Master’s degree in Physics and a PhD in technology management from the federal institute of technology in Zurich, Switzerland. He also founded his own tech startup.
As Head of Commercial Development, Nicki manages strategic partnerships with key companies, Universities, and NHS organisations, and support SMEs developing innovations for health and social care. Nicki is a clinician with 30 years’ experience in the NHS working in a broad range of roles nationally and locally, including quality improvement, service redesign and acute care commissioning. Nicki has also worked as a consultant to pharmaceutical companies and for a market access consultancy. Since joining Oxford AHSN in 2014 Nicki has led a £2.4m collaborative bid for a Life Sciences Innovation Centre in Buckinghamshire and provides Board level leadership to two digital SME programmes, Bucks HSCVentures and The Hill. Nicki has led the Digital Health programme within the Oxford AHSN region since 2016, producing the digital health roadmap and two successful Innovate UK Digital Health Technology Catalyst bids.
Damien is charged with extending Voluntis' real-world evidence capabilities, notably in the fields of outcomes measurement and data valuation. He trained in the UK as a pharmacist and computer scientist. He has over 15 years of experience in the pharmaceutical industry and in frontline clinical healthcare (at Portsmouth Hospitals NHS Trust and multiple pharmacies). He notably worked at AXA, where he helped build an operational framework to handle outsourced medical information services for pharmaceutical partners. In 2005 he led the preparation for the first ever UK Medicines and Healthcare Products Regulatory Agency inspection of this type of provider. He joined Voluntis in Paris in 2008 to take the helm of its quality division, obtaining QMS certification for ISO:13485 in 2010 and VITM/Diabeo’s CE Mark in 2013.
Elan is an investor with JAZZ Venture Partners focused on technologies that unlock human potential, such as prescription digital therapeutics. Portfolio companies include Pear Therapeutics and Akili Interactive. Previously Elan has started and grown several venture-backed startups as an operator and adviser across digital health, AI, and neurotech. Other experiences at the Boston Consulting Group and Monitor Deloitte, where he advised executives in the life sciences, provider, payer, and regulatory spaces. He received his BA from Tufts University and his MBA from the University of California, Berkeley.
“I really enjoy DTx. The focused agenda keeps the audience well engaged and I learn a lot from the diverse insights and perspectives from the audience. It’s fantastic to have such a cross-sector showing at the summit”
Joris Van Dam, Executive Director, Head of Digital Therapeutics, Novartis
Conference Workshops
Tuesday, 18th of June 2019
Conference Workshops at DTx Europe have been specifically designed to enhance attendee’s learning experiences at the event.
These three-hour sessions will allow you to have your fundamental questions answered by experts in great detail.
Click to download full details of the conference workshops.
Workshop Leaders
Austin Speier, Chief Strategy Officer, Click Therapeutics
Konstantin Mehl, Chief Executive Officer, Kaia Health
Damien McKeon, Vice President, Real-World Evidence, Voluntis
9:00 Presentation: What is the Current State of Play with the Digital Therapeutics Industry?
9:30 Breakout Discussions
Splitting into smaller working groups, each group will discuss their current views on digital therapeutics as a concept and their views on the different facets of the industry.
- Are we comfortable with the definition of a digital therapeutic?
- What are the different business models being pursued by digital therapeutic companies?
- Generally speaking, how do insurers, pharma and regulatory authorities view digital therapeutics?
- What lessons can we draw on from working with other related industries?
- What remaining questions do we have about digital therapeutics?
10:30 Refreshment Break
11:00 Feedback Discussions
Representative(s) from each group share the main points from their discussion to the whole group. Additional questions form moderators and other group members will be raised during this collaborative discussion.
12:00 End of Workshop
Leave this workshop with:
- Fundamental questions answered around what a digital therapeutic is being defined as compared to other digital interventions
- A deeper understanding of the current insurers and hospitals perspectives on digital therapeutics and how these are looking to be advanced
- Up-to-date information on the different ways pharma are involved in the industry
- Strong appreciation for the regulatory landscape of digital health
- A stronger appreciation of the crucial questions facing the industry that will be tackled during the rest of the Summit.
Workshop Leaders
Yuri Maricich, Chief Medical Officer, Pear Therapeutics
Ed Cox, Chief Executive Officer, Dthera Sciences
Mette Dyhrberg, Chief Executive Officer, Mymee
1:00 Presentation: What are the Fundamentals of the Digital Therapeutics Landscape in the USA?
1:30 Breakout Discussions
Splitting into smaller working groups, each group will discuss their current views on the U.S. landscape and discuss specific questions, including:
- What are the fundamental building blocks of the U.S. healthcare system?
- How are digital therapeutic companies working with large employers to secure reimbursement?
- How are digital therapeutic companies working with private payers and providers to obtain reimbursement?
- What does the current regulatory landscape look like in the U.S.?
- What are the opportunities for European companies to expand into the U.S.?
2:30 Refreshments
3:00 Feedback Discussions
Representative(s) from each group share the main points from their discussion to the whole group. Additional questions form moderators and other group members will be raised during this collaborative discussion.
4:00 End of Workshop
Leave this workshop with:
- A fundamental understanding of the US healthcare system and how it relates to digital health
- A deeper understanding of the go-to-market strategies that are leading the way in the U.S.
- Up-to-date information on the current digital health regulatory landscape
- Food for thoughts on the ways to expand into the U.S.
- A deeper understanding of the likely future direction of the digital therapeutics landscape in the U.S.
Summit Agenda
Click to download our full event agenda.
8:00 Registration, Breakfast & Networking
9:00 Chair’s Opening Remarks & Setting the Scene
Marc Sluijs, Founder, DigitalHealth.Network
Digital Therapeutics: The Next Generation of Healthcare
9:10 Keynote Presentation: Lessons Learnt from the Frontline of Digital Therapeutics – Pear Therapeutics
Yuri Maricich, Chief Medical Officer, Pear Therapeutics
9:35 Keynote Presentation: Lessons Learnt from the Frontline of Digital Therapeutics – WellDoc
Anand Iyer, Chief Strategy Officer, WellDoc
9:50 Panel: Advancing the Next Generation of Healthcare: The Crucial Questions Facing Digital Therapeutics
Jessica Shull, Digital Health Manager, Bellvitge University Hospital | Strategic Advisor, DTA
Lana Ghanem, Managing Director, Hikma Ventures
Anand Iyer, Chief Strategy Officer, WellDoc
Edward Kliphuis, Investment Director, M Ventures
Yuri Maricich, Chief Medical Officer, Pear Therapeutics
10:20 Morning Refreshments & Networking
Under the Microscope: Crucial DTx Questions
These small group discussions provide a unique opportunity to get into the key detail of the challenges and opportunities of crucial questions facing digital therapeutics. Each session has been curated to bring expert moderators together in order for attendees to find questions in a peer-to-peer format.
Attendees will be able to attend 2 roundtables, which are 40 minutes each. Get ready for plenty of takeaways in this 80-minute session!
11:00 Workshop Session A
Roundtable 1A: Clinical Workflow Integration: Getting Your Digital Therapeutics Prescribed and Monitored from the Clinician’s EMRt
Brian Clancy, Co-Lead & Associate Director, AppScript, IQVIA
Michael Krupnick, Director of Product, AppScript, IQVIA
Roundtable 2A: The UK Landscape – Routes to Entry and Learning from Best Practice
Neelam Patel, Chief Operating Officer, MedCity
Leanne Summers, Digital Strategy Delivery Lead, NHS England
Nicki Bromwich, Head of Commercial Development, Oxford AHSN
Roundtable 3A: What Partnership Models are Companies Adopting to Accelerate Implementation and Commercialization?
11:40 Workshop Session B: Time to Switch!
Roundtable 1B: Clinical Workflow Integration: Getting Your Digital Therapeutics Prescribed and Monitored from the Clinician’s EMRt
Brian Clancy, Co-Lead & Associate Director, AppScript, IQVIA
Michael Krupnick, Director of Product, AppScript, IQVIA
Roundtable 2B: The UK Landscape – Routes to Entry and Learning from Best Practice
Neelam Patel, Chief Operating Officer, MedCity
Leanne Summers, Digital Strategy Delivery Lead, NHS England
Nicki Bromwich, Head of Commercial Development, Oxford AHSN
Roundtable 3B: What Partnership Models are Companies Adopting to Accelerate Implementation and Commercialization?
12:20 Lunch & Networking
Implementing & Reimbursing Digital Therapeutics
2:00 Presentation: Digital Therapeutics for Back Pain – Reimbursement in Germany
Konstantin Mehl, Chief Executive Officer, Kaia Health
2:25 Presentation: Developing and Implementing Neurorehabilitation Digital Therapeutics
Kim Baden-Kristensen, Co-Founder & Chief Executive Officer, Brain+
2:50 Presentation: Where Digital Therapeutics Meet Value-Based Care
Jim O’Donoghue, President, S3 Connected Health
3:15 Presentation: Developing and Scaling Digital Therapeutics Across Multiple Disease States
Matthias Zenker, Partner, GAIA AG
3:40 Afternoon Refreshments & Networking
Healthcare Ecosystem Perspectives
4:10 Panel: Creating an Ecosystem – Enabling Integration of Digital Health Technologies
Indra Joshi, Digital Health and AI Clinical Lead, NHS England
Sam Roberts, Director, Innovation and Life Sciences, NHS England
Mark Salmon, Program Director, NICE
Hakim Yadi, Chief Executive Officer and Co-Founder, Closed Loop Medicine
4:50 Panel: Healthcare Ecosystem Perspectives: Building Frameworks for Digital Therapeutics
Marco Marsella, Head of eHealth, Wellbeing and Ageing Unit, European Commission
Elena Mustatea, CEO & Co-Founder, Bold Health
Vincent Hennemand, VP, Strategy, Corporate and Business Development, Akili Interactive
Matthias Kuss, Head of Health Innovation Center, Allianz Partners
Bechara Saab, Co-Founder, Chief Scientist & Chief Executive Officer, Mobio Interactive
5:30 Drinks Reception
6:30 Close of Day 1
Download Agenda to access full details of the event…
8:00 Breakfast & Networking
9:00 Chair’s Opening Remarks
Ed Cox, Chief Executive Officer, Dthera Sciences
Pharma & Digital Therapeutics
9:10 Presentation: Commercializing and Scaling Prescription Digital Therapeutics
André Heeg, Chief Digital Officer, Sandoz
9:40 Fireside Chat: Pharma & Digital Therapeutic Partnership – Click Therapeutics & Otsuka
David Klein, Chief Executive Officer, Click Therapeutics
Sahil Kirpekar, Head, Business Development, Europe, Otsuka Pharmaceuticals
10:10 Panel: Pharma and Digital Therapeutics: The Go-to Partnership Model?
Eugene Borukhovich, Global Head, Digital Health Incubation & Innovation, Bayer
Steve Burns, VP, Project Leadership and Digital Therapeutics, AstraZeneca
Florian Schubert, Director, Digital Strategy, Sandoz
Alexandre Capet, Chief Operating Officer, Voluntis
Rana Lonnen, Head, Search and Evaluation Strategic Capital, Novartis
10:55 Morning Refreshments & Networking
Digital Therapeutics Showcase
11:25 Presentation: Developing Digital Therapeutics to Enable Healthy Aging
Arfa Rehman, Chief Executive Officer & Co-Founder, Virtue Health
11:45 Presentation: Developing and Scaling Digital Sedation
Mario Huyghe, Chief Executive Officer, Oncomfort
12:05 Presentation: How to Build and Scale Digital Therapeutics in Emerging Markets
Abhishek Shah, Chief Executive Officer, Wellthy Therapeutics
12:25 Presentation: Developing Digital Therapeutics to Combat Cancer-related Fatigue
Door Vonk, Co-Founder & CCO, Tired of Cancer
Atse Aukes, Head of Product, Tired of Cancer
12:45 Lunch & Networking
Shaping the Future of the Industry
1:45 Panel: Industry Goals, Market Predictions and Take Home Messages
Mario Huyghe, Chief Executive Officer, Oncomfort
Arfa Rehman, Chief Executive Officer & Co-Founder, Virtue Health
Abhishek Shah, Chief Executive Officer, Wellthy Therapeutics
Door Vonk, Co-Founder & CCO, Tired of Cancer
Elan Tye, Investor, JAZZ Venture Partners
2:30 Chair’s Summary
Ed Cox, Chief Executive Officer, Dthera Sciences
2:40 Close of DTx Europe 2019
Download Agenda to access full details of the event…
“DTx is a great event! There is a great mix of digital innovators and large companies which deliver high-quality content. I learn a lot and it’s great to see this community come together and have authentic interactions”
Adam Kaufman, CEO, Canary Health
DTx Europe Venue
De Vere Grand Connaught Rooms, Central London
We strive to provide inspirational venues that can provide the space needed for an open and widely networked event.
The 2019 summit is being held in the De Vere Grand Connaught Rooms, an iconic event venue in the heart of Covent Garden.
With arched ornate ceilings, beautiful wood-paneling and dramatic chandeliers, the Connaught Rooms creates an impressive event space perfect for learning, networking and relaxing.
The De Vere has provided a useful list of recommended local hotels for you to stay at, which is included the welcome pack.
Registration
Sponsorship
The DTx summits are the premier events for senior executives from DTx companies, Pharma, Investors, HCPs and Payers.
DTx Europe 2019 is the fourth summit in the series, the first three were sell-outs. We are expecting 100 people at the summit in London, which is what our attendees and sponsors tell us is the optimum size.
We believe that getting the right mix of sponsors is critical for a successful summit for you and our attendees. The DTx summit provides a rare opportunity to showcase your business to a world class audience.
You will be impressed with our service and truthfulness. We will be honest with you throughout the process from deciding which option is right for you to delivery on-site.
With four companies confirmed pre-launch, sponsor and supporter spaces are selling fast. Get in touch today to learn more to avoid missing out!
Contact Us
